Migraines

Monthly Subcutaneous Galcanezumab Effective for Migraine Prevention

Monthly Subcutaneous Galcanezumab Effective for Migraine Prevention

By

Monthly subcutaneous injections of galcanezumab at either 120 mg or 300 mg were effective for preventing migraines.

Intranasal Sumatriptan Increases Risk for Taste Disturbance

Intranasal Sumatriptan Increases Risk for Taste Disturbance

By

The use of intranasal sumatriptan is an effective treatment for patients with acute migraine attacks; however, future investigations are needed to better understand differences in routes of administration and other therapies for migraine.

Migraines and Gastrointestinal Disorders: Examining the Connection

Migraines and Gastrointestinal Disorders: Examining the Connection

By

A recent study by Doulberis and colleagues provides a comprehensive summary of the relevant published studies linking migraine and gastrointestinal or related disorders.

FDA Approves Cefaly for Acute Treatment of Migraine

FDA Approves Cefaly for Acute Treatment of Migraine

By

Cefaly Technology announced that the FDA has cleared for use the Cefaly Acute medical device for the treatment of migraines, with or without aura, in patients ≥18 years of age.

Podcast: What You Should Know About Migraine Subtypes

Podcast: What You Should Know About Migraine Subtypes

By

Even though there's a variety of migraine subtypes on the books, there are two major subtypes: migraine without aura (characterized with specific features and associated symptoms) and migraine with aura (transient neurological symptoms that proceed or accompany a headache).

Sign Up for Free e-Newsletters